Sangeetha T, Darlin Quine S
School of Chemical and Biotechnology, SASTRA-Deemed University, Thirumalaisamudram, Tanjore - 613402, Tamil Nadu, South India.
J Pharm Pharmacol. 2006 May;58(5):617-23. doi: 10.1211/jpp.58.5.0006.
The present study was designed to evaluate the preventive effect of S-allyl cysteine sulfoxide (SACS) in isoproterenol (ISO)-induced myocardial ischaemia in male Wistar rats. Rats were pretreated with SACS (40 and 80 mg kg(-1) body-weight) for 5 weeks. After the treatment period, ISO (150 mg kg(-1) body-weight) was administered subcutaneously to rats at intervals of 24 h for 2 days. The activities of creatine kinase, creatine kinase-MB, lactate dehydrogenase, aspartate transaminase and alanine transferase were significantly increased in serum and significantly decreased in the hearts of ISO-treated rats. Pretreatment with SACS decreased the activities of these enzymes significantly in serum and significantly increased the activities in heart in ISO-treated rats. The levels of cholesterol, triglycerides and free fatty acids increased in serum and heart, while the levels of phospholipids increased in serum and decreased in heart in ISO-treated rats. SACS pretreatment showed a significant effect on the lipids studied. The activity of 3-hydroxy 3-methyl glutaryl coenzyme A (HMG CoA) reductase was significantly increased and the activity of lecithin cholesterol acyl transferase (LCAT) was significantly reduced in ISO-induced rats. Oral pretreatment with SACS significantly decreased the activity of HMG CoA reductase and significantly increased the activity of LCAT in ISO-induced rats. The levels of plasma thiobarbituric acid reactive substances and hydroperoxides were increased in ISO-treated rats. Pretreatment with SACS significantly decreased the levels of lipidperoxides in ISO-treated rats. The effect at a dose of 80 mg kg(-1) body-weight was more effective than at a dose of 40 mg kg(-1) body-weight and brought back all the biochemical parameters to near normal levels. Thus our study shows that SACS has a lipid-lowering effect in ISO-induced rats. Our study may have clinical relevance.
本研究旨在评估S-烯丙基半胱氨酸亚砜（SACS）对异丙肾上腺素（ISO）诱导的雄性Wistar大鼠心肌缺血的预防作用。大鼠用SACS（40和80毫克/千克体重）预处理5周。治疗期结束后，以24小时的间隔皮下给予大鼠ISO（150毫克/千克体重），共2天。ISO处理的大鼠血清中肌酸激酶、肌酸激酶-MB、乳酸脱氢酶、天冬氨酸转氨酶和丙氨酸转氨酶的活性显著升高，而心脏中的活性显著降低。SACS预处理显著降低了ISO处理大鼠血清中这些酶的活性，并显著提高了心脏中的活性。ISO处理的大鼠血清和心脏中胆固醇、甘油三酯和游离脂肪酸的水平升高，而血清中磷脂水平升高，心脏中磷脂水平降低。SACS预处理对所研究的脂质有显著影响。在ISO诱导的大鼠中，3-羟基-3-甲基戊二酰辅酶A（HMG CoA）还原酶的活性显著增加，卵磷脂胆固醇酰基转移酶（LCAT）的活性显著降低。SACS口服预处理显著降低了ISO诱导大鼠中HMG CoA还原酶的活性，并显著提高了LCAT的活性。ISO处理的大鼠血浆硫代巴比妥酸反应性物质和氢过氧化物的水平升高。SACS预处理显著降低了ISO处理大鼠中脂质过氧化物的水平。80毫克/千克体重剂量的效果比40毫克/千克体重剂量更有效，并使所有生化参数恢复到接近正常水平。因此，我们的研究表明SACS对ISO诱导的大鼠有降脂作用。我们的研究可能具有临床相关性。
